NCRI Press Release, 8 November 2010
Date published: Nov 08 2010
Test selects 60 per cent of women with inherited ovarian cancer who could benefit from ‘smart’ drug
Download the attachment
Recent Tweets
-
Hear @Amocras patient perspective on presenting a dichotomy or identifying an opportunity for clinical trial design… https://t.co/aDPVM8LtYd
4 days ago -
The impact of #COVID19 on the psychological, social, behavioural aspects of cancer care has been discussed in recen… https://t.co/EGkwUjcCkJ
4 days ago -
. @NCRI_partners and @britsocimm are working together to advance our understanding of cancer #immunology and… https://t.co/aE2qg9Kytg
4 days ago
- 19 Mar 2020Workstream leads: NCRI Skin Group
- 26 Nov 2019CM-Path - Application for Consumer Membership (Deadline - 1st January 2020)
- 20 Nov 2019With its new chair, Professor David Harrison, at the helm, CM-Path share top priorities
- 19 Jul 2019Consumer (Patient / Carers) vacancies for NCRI Groups available. Apply today!
- 20 May 2019Celebrating ten years of NCRI’s Clinical and Translational Radiotherapy Research Group
- 29 Apr 2019NCRI and The British Society for Immunology announce new partnership
- 14 Mar 2019Register now for the NCRI CTU Annual Trials Meeting: 17 June 2019
RSS Feed